Aspartyl-tRNA synthetase-Fc conjugates
AssigneeaTyr Pharma, Inc.
InventorsYing Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Jeffrey D. Watkins, John D. Mendlein
Life of this patent
Estimating the term…
Abstract
The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
Claims16
An aspartyl-tRNA synthetase (DRS) fusion polypeptide, which comprises an amino acid sequence at least 95% identical to SEQ ID NO:36.
Dependencies are inferred from the claim text.